Universal screening of Lynch syndrome is ready for implementation

Marco Di Marco¹, Elvira D'Andrea^{2

3}, Paolo Villari²

Affiliations

¹ Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. marcodimarco@live.it.
² Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
³ Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.

Free article

Comment

Marco Di Marco et al. Genet Med. 2019 Jan.

Free article

. 2019 Jan;21(1):254-255.

doi: 10.1038/s41436-018-0027-3. Epub 2018 May 8.

Marco Di Marco¹, Elvira D'Andrea^{2

3}, Paolo Villari²

¹ Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. marcodimarco@live.it.
² Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
³ Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.

No abstract available

Comment on

Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.
Di Marco M, DAndrea E, Panic N, Baccolini V, Migliara G, Marzuillo C, De Vito C, Pastorino R, Boccia S, Villari P. Di Marco M, et al. Genet Med. 2018 Oct;20(10):1131-1144. doi: 10.1038/gim.2017.244. Epub 2018 Jan 4. Genet Med. 2018. PMID: 29300371 Free PMC article.
Is universal tumor testing for Lynch syndrome cost-effective? It depends!
Grosse SD. Grosse SD. Genet Med. 2019 Jan;21(1):252-253. doi: 10.1038/s41436-018-0025-5. Epub 2018 May 15. Genet Med. 2019. PMID: 29765139 Free PMC article. No abstract available.

1. Di Marco M, D’Andrea E, Panic N, et al. Which Lynch syndrome screening programs could be implemented in the “real world”? A systematic review of economic evaluations. Genet Med. 2018. https://doi.org/10.1038/gim.2017.244 . - DOI
1. Grosse S. Is universal tumor testing for Lynch syndrome cost-effective? It depends! Genet Med. 2018 (this issue).
1. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12:93–104. - DOI
1. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796–7. - DOI
1. Canadian Agency for Drugs, Technologies in HealthDNA Mismatch Repair Deficiency Tumour Testing for Patients with Colorectal Cancer: A Health Technology Assessment. CADTH Optimal Use Report, vol. 5, no. 3b). Ottawa, Canada, 2016.